[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100315173":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":38,"centralContacts":43,"locations":49,"responsibleParty":68,"collaborators":24,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":24,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":24,"maxAge":78,"enrollmentInfo":79,"targetDuration":24,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":52,"whyStopped":24,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Sclnow Biotechnology Co., Ltd.","INDUSTRY",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose mesenchymal stem cells","EXPERIMENTAL","Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",[13,14],"Biological: Low dose mesenchymal stem cells","Procedure: Intraarticular injection",{"label":16,"type":10,"description":17,"interventionNames":18},"High dose mesenchymal stem cells","High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",[19,14],"Biological: High dose mesenchymal stem cells",{"label":21,"type":22,"description":23,"interventionNames":24},"Control groups","NO_INTERVENTION","No intervention",null,[26,30,33],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":24},"BIOLOGICAL","Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \\* 10\\^7 cells (5ml);",[9],{"type":27,"name":16,"description":31,"armGroupLabels":32,"otherNames":24},"Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \\* 10\\^7 cells (5ml)",[16],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":24},"PROCEDURE","Intraarticular injection","Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group",[16,9],[39],{"name":40,"affiliation":41,"role":42},"Hongbin Lu","Xiangya Hospital of Central South University","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":24,"email":48},"Lei Guo","CONTACT","861064368977","georgeguo@sclnow.com",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Xiangya Hospital Central South University","RECRUITING","Changsha","Hunan","410008","China","CN",{"type":59,"coordinates":60},"Point",[61,62],112.97087,28.19874,{"lat":62,"lon":61},[65],{"name":40,"role":46,"phone":66,"phoneExt":24,"email":67},"15874889777","hongbinlu@hotmail.com",{"type":69,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100315173","phase-2-the-safetyefficacy-of-huc-mesenchymal-stem-cells19isclife-oa-therapy-for-patients-with-osteoarthritis-100315173",false,"NCT03383081","The Safety\u002FEfficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis","A Clinical Research on the Safety\u002FEfficacy of Human Umbilical Cord Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis","Inclusion Criteria:\n\n* Diagnosis of Knee Osteoarthritis by Kellgren and Lawrence Grading Scale, classified with Grade 2-3\n* Confirm with cartilage injury,articular cartilage part or full-thickness injury, by MR (Magnetic Resonance)\n* Age \\\u003C70, no serious organ dysfunction\n* Over 2 years knee pain or no very effective with conservative treatments\n* Knee pain of VAS (visual analog scale score) is 4 or higher\n* Normal hepatic and renal function, no history of gout, rheumatoid arthritis, and autoimmune diseases, etc.\n* Understand and sign the consent form of this study\n\nExclusion Criteria:\n\n* Refuse to sign the consent form, or cannot keep follow-up visit\n* Age \\>70; Age \\\u003C70, but with multiple organ failure\n* Unstable vital signs (breath, blood pressure, pulse)\n* Combined with knee ligament (anterior and the posterior cruciate ligament, medial and lateral collateral ligament) rupture, laxity, etc.\n* Serious bleeding tendency, poor coagulation function (PTA \\\u003C35%)\n* Pregnant or breast feeding women, or positive pregnancy test in 7 days before treatment\n* Participate other clinical experiments in 3 months\n* With progressing malignant tumor\n* Combined with shock and critically ill patients\n* With mental disease, cannot\n* With history of knee joint infection, surgery, and radiotherapy\n* With immunosuppressive agents treatment in 6 weeks\n* Injection with hormones and sodium hyaluronate in joint in 3 months\n* Overweight expressed as body mass index (BMI) \\>35\n* With skin disease around knee joint\n* With Immunodeficiency disease, including long term use immunosuppressive agents patients\n* Combined with serious infection\n* With some other conditions that doctor propose not to participate","ALL","70 Years",{"count":80,"type":81},60,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","The purpose of this study is verify the efficacy and safety of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) therapy for patients with Osteoarthritis, and in addition, provide basis for exploring the treatment regimen of UC-MSC therapy in different degree of cartilage defect disease",[87],"Osteoarthritis, Knee",[89],"osteoarthritis, mesenchymal stem cell","2025-12-02",{"date":92,"type":93},"2025-12-04","ACTUAL",{"date":95,"type":93},"2018-10-01",{"date":97,"type":81},"2026-12-31",{"name":5,"class":6},1]